Fig 1: N. meningitidis challenged human neutrophils produce EBI3, which can attenuate the neutrophil-chemoattractant responses of primary human astrocytes. Panels A-B: neutrophilic cells (Neut) and differentiated U937 monocyte-like cells (Mono) were untreated (0), or exposed to IFN-β (1 ng/mL), IFN-γ (10 ng/mL), LPS (10 and 100 ng/mL for Neut and Mono, respectively), N. meningitidis-derived LOS (100 ng/mL) or N. meningitidis (MOI of 50) for 24 h prior to immunoblot analysis for EBI3 and β-actin (A) and EBI3 release by ELISA (B). Relative EBI3 protein expression was determined by densitometric analysis normalized to untreated cells. Data shown is the mean +/− SEM (n = 3). Asterisks indicate a significant difference from untreated cells (one-way ANOVA; p < 0.05). Panel C: Astrocytes were untreated (0) or treated with rEBI3 (5 and 10 ng/mL) for 24 h prior to cell viability assessment (OD 490 nm). Panel D: Astrocytes were untreated (0) or challenged with flagellin (Flg, 25 ng/mL), LPS (10 ng/mL), or N. meningitidis (MOI of 10, 25, and 50) plus or minus rEBI3 (10 ng/mL) for 8 or 24 h. Data shown is mean +/− SEM of at least 2 independent experiments and asterisks and daggers indicate significant differences from untreated cells and similarly challenged cells, respectively (two-way ANOVA; p < 0.05).
Supplier Page from Abcam for Recombinant Human EBI3 protein